ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.17% | 31.65% | 57.86% | 52.44% | 54.97% |
| Total Depreciation and Amortization | 9.90% | 13.23% | 14.58% | 10.77% | 2.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 205.25% | -160.10% | -136.00% | -179.36% | 8.37% |
| Change in Net Operating Assets | -127.34% | -125.48% | -129.34% | -124.85% | 1,051.72% |
| Cash from Operations | -272.57% | -440.61% | -1,335.94% | -2,585.56% | 131.45% |
| Capital Expenditure | -3.73% | -148.87% | -199.70% | -240.31% | -96.54% |
| Sale of Property, Plant, and Equipment | -- | -75.22% | -75.22% | -75.22% | 955.74% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -143.14% | -- | -- | -- | -- |
| Cash from Investing | -189.90% | 651.75% | -2,155.49% | -2,454.08% | 714.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 39.83% | -54.39% | 94.23% | 93.40% | 94.16% |
| Issuance of Common Stock | 20,198.87% | -97.38% | -96.29% | -96.35% | -97.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,145.25% | -119.03% | 92.78% | 91.41% | 92.07% |
| Foreign Exchange rate Adjustments | 8.58% | 63.45% | -98.31% | -85.04% | -91.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.49% | -255.76% | -105.98% | -116.71% | 126.53% |